Download April 1, 2009 - mArch 31, 2010 AnnuAl report

April 1, 2009 - march 31, 2010
annual report
Contents
AWARENESS
SUPPORT
research
01
Table of Contents
02
President & CEO’s Message
03
Chair’s Message
04
SMAC Chair’s Message
05
Prostate Cancer Canada Network
06
Research
08
Guidelines for Early Detection
14
Donors
17
Board of Directors / SMAC
18
Condensed Financial Statements
01
prostatecancer.ca
President’s Message
Leadership. Not the leadership of an individual, but of an organization. In the fight against prostate cancer, the
goal of Prostate Cancer Canada has been to assume the leadership position and stand up for survivors and their
families across Canada, while continuing to raise awareness and fund vital research which will someday lead to
a cure.
This is why we take a strong stand in support of early detection through the PSA test. We know there is
controversy surrounding the PSA test, and stakeholders around the world are debating its merits. While we
listen very closely to the opinions of doctors, researchers, scientists, and other prostate cancer experts, the
people we trust the most are the prostate cancer survivors, those who have been directly impacted. Over and
over again, survivors tell us the same thing: the PSA test was the red flag that alerted them (and their doctor)
to a potential problem. Over and over again, we have heard them say, “the PSA test saved my life.”
At Prostate Cancer Canada we believe it is important for leaders to rise above debates on issues like this.
02
“We believe the best approach is to inform and educate Canadians on all aspects of
a controversy, and so, we present both sides of the story, while also clearly articulating
our position.”
Chair’s Message
The past 12 months have been full of continuing success for Prostate Cancer Canada. Led by a very strong,
engaged Board of Directors, composed of leaders from the business and healthcare communities, and an
experienced, dedicated staff committed to our cause, we are quickly becoming known as the Canadian leader
in the battle against the most common cancer to afflict Canadian men.
As a prostate cancer survivor, I know firsthand the challenges faced by men and their loved ones following a
prostate cancer diagnosis. Because of this, I remain as determined as ever to support Prostate Cancer Canada as
it unites Canadians from coast to coast, raising needed funds for research, education, support and awareness.
I will be stepping down as Chair of the PCC Board of Directors in September 2010. I have had the privilege of
serving as Chair for the past 3 years, seeing the organization through much change. While I will remain on the
Board for the foreseeable future as past Chair, it is time to leave the leadership role, and I do so with gratitude
to my fellow directors, staff and all of the volunteers who have played a part in our success story.
The next 12 months promise to be exciting, invigorating and full of promise for a better future. I look forward to
seeing Prostate Cancer Canada become more prominent in the lives of Canadians, as we work diligently to raise
awareness for this disease. We look forward to the challenges ahead.
03
This annual report is unique, in that in addition to subjects traditionally found in a periodical such as this, we
also include a section on the PSA test . We hope you find it informative.
Thanks to our staff, Board of Directors, and to all those who have worn the tie or scarf, donated to our organization,
and/or volunteered precious time to join the fight. We are privileged to work for you and with you.
Steve Jones
President & CEO
“As a prostate cancer survivor, I know first hand the challenges faced by men and their
loved ones following a prostate cancer diagnosis.”
Lee Watchorn
Chair, Board of Directors
prostatecancer.ca
A message from the Chair of the Scientific
& Medical Advisory Committee
Prostate cancer canada network
This has been an exciting time for Prostate Cancer Canada. Being the only national organization that is solely
committed to the elimination of prostate cancer through research, education, support, and awareness, we find
ourselves closer to reaching our vision of being a global leader in the fight against this disease.
With the merger of the Canadian Prostate Cancer Network (CPCN) with Prostate Cancer Canada, and its revitalization
under the new name, Prostate Cancer Canada Network (PCCN), we have crossed the threshold into a new era of
support for the hundreds of thousands of Canadian men currently living with prostate cancer and the 24,600 that
will be diagnosed this year.
This year we reached new heights as we offered the largest amount of funding for grants and awards since
the inception of the PCC research program. Over $2.4 million was awarded to 19 promising researchers, whose
proposals demonstrated the highest scientific merit and displayed the most relevance to PCC’s mandate of
aiming to achieve the greatest impact on the prevention, detection and treatment of prostate cancer.
We recently embarked upon a ground-breaking initiative, where PCC has taken the lead in an International
Cancer Genome Consortium (ICGC). This study is expected to generate high quality data which will meet
global standards for genome sequencing projects and will be shared with researchers worldwide. It is
considered to be the most important prostate cancer project in history, for the following reasons:
04
1. It will involve testing bio-banked material from prostate cancer patients around the world which can
assist in the identification of genetic alterations that are related to aggressive cancer and treatment failures.
2. Information may be used to develop improved diagnostic methods which could assist with determining
the types of cancers that require immediate treatment as well as those that can be monitored.
3. New therapies can be created to treat prostate cancer which is resistant to existing treatments.
4. It may lead to improvements in screening procedures and treatment strategies.
“While we look forward to continued advancements at Prostate Cancer Canada, it
is with unwavering dedication that we remain committed to improving the lives of
men who are affected by prostate cancer worldwide.”
Our network of independent support groups blend well with PCC’s national strategies, putting a local face in the
media and with the general public. PCCN affiliated groups are encouraged to ‘work local, think national’ because as
one voice on the national stage we are more powerful and have increased visibility when it comes to local efforts
and activities. Group work includes monthly meetings, one-on-one hospital visits, newsletters, awareness sessions,
and presentations at health fairs and service clubs like Rotary, Gyro, and Lions.
“Our local groups enjoy excellent relationships with medical professionals in their community
and give freely of their time to help educate and consult.”
When media calls, knowledgeable survivors are ready to tell their personal stories. Support groups put a local face
to this, the most common cancer to afflict Canadian men. Groups also participate in PCC events such as Wake Up Call
Breakfasts, Safeway Father’s Day Walk/Run and Movember.
05
Although prostate cancer is an exclusively male disease, it often has a profound impact on the family unit. Many
groups recognize this and facilitate special meetings for women only. These small meetings allow women to share
their feelings and concerns in a non-threatening, intimate manner.
In September, during Prostate Cancer Awareness Week (September 19-25), PCCN will be hosting the 7th Annual
National Support Group Conference. The event will be held at the Fairmont Royal York in Toronto. This conference
will bring together support group leaders from across the country. During the two and a half days we will celebrate
and learn about the achievements of Canadian prostate cancer researchers and participate in workshops designed to
strengthen and help grow the groups.
As the Prostate Cancer Canada Network grows in size, stature and visibility, the mission of Prostate Cancer Canada
will likewise benefit, leading to increased resources for research, awareness, support and advocacy.
Dr. Yves Fradet, MD, FRCSC
Chair, Scientific Medical Advisory Committee
Every day the team at Prostate Cancer Canada demonstrates their enthusiasm for the Network in many ways – from
fielding and passing on telephone enquiries from the newly diagnosed, to sharing expertise in areas like marketing,
community development and advocacy. The partnership of Prostate Cancer Canada, Prostate Cancer Canada Network
and our local support groups is truly making a difference to the lives of Canadian men and their families.
Bob Shiell
Prostate Cancer Canada Network
prostatecancer.ca
RESEARCH
RESEARCH (continued)
Canadian BRCA 1/2 Prostate Cancer Network
Pilot Grants
Generously supported by CIBC and RSM Richter
Thanks to the generosity of our donors and sponsors, PCC embarked on several exciting research initiatives.
A few examples of the research funded by PCC are provided below.
Every woman is born with the BRCA1 (breast cancer gene 1) and BRCA2 (breast cancer gene 2) genes. When
functioning normally, these genes do not pose any risk to a woman’s health. However, some women may be
born with or experience mutations of the BRCA genes through their lifetime. Women who have BRCA mutations
are at increased risk for developing breast cancer compared with women who do not have these mutations.
Early studies have shown that the male relatives of these women have a higher susceptibility to developing
prostate cancer—as much as a 22-fold excess risk. It’s also evident that these men will be diagnosed with
aggressive forms of the disease younger than the typical prostate cancer patient and have a higher chance of
dying from it.
06
Prostate Cancer Canada is bringing together leading Canadian researchers to assess male carriers of BRCA 1/2 ,
including those who have not been diagnosed with prostate cancer, through analysis of their saliva or blood.
The goal will be to offer novel and individualized treatments for BRCA 1/2 - associated aggressive cancers.
This five-year project will support genetic screening of hundreds of men through DNA sequencing. It will benefit
from the input of experts in the fields of genomic counseling and surgical, radiation and medical oncology.
The results will help with the development of new approaches to disease prevention and treatment through
early genetic assessment.
As there is currently no group of researchers specifically studying this rare group
of patients in Canada, Prostate Cancer Canada is proud to lead the charge in this
exciting collaborative effort.
In 2009, PCC sponsored 17 pilot studies across Canada. One such research project led by principal investigator
Rajiv Chopra of Sunnybrook Health Sciences Centre investigated the potential for magnetic resonance elastography
(MRE) to help detect prostate cancer. Prostate tumors are often stiffer than the surrounding gland, and MRE
may enable doctors to better locate cancer within the prostate. This research team built prototype devices that
would allow the use of high resolution MRE in prostates and tested these devices in preliminary experiments.
Based on positive results, the researchers are planning initial clinical trials to investigate the role of MRE for
prostate cancer detection.
In another pilot study, Dr. Rob Bristow and his colleagues at the Princess Margaret Hospital, studied cells and
tissues taken from prostate cancer patients to see if there were defects in DNA repair mechanisms that could
be damaged by radiotherapy or chemotherapy treatment.
DNA in a cell can be damaged by a variety of factors like radiation and UV light. Cells find and fix damage to
the DNA in a collection of processes called DNA repair. Recent studies suggest that some prostate cancer patients
have defects in the DNA repair processes, leading to an increased risk of developing cancer and perhaps more
aggressive forms of the disease.
07
They found that a number of DNA repair pathways were abnormal at the DNA
and RNA levels.
To confirm their findings from the laboratory, they studied cell lines and actual prostate cancer tissues to see if
the same defects exist in prostate cancer patients’ tumors. They found that a number of DNA repair pathways
were abnormal at the DNA and RNA levels. Drugs designed to reverse this abnormality were successful in
vitro (in tissue culture) which supports a proof of principle that this study could lead to the creation of a new
diagnostic test which will help personalize treatments.
prostatecancer.ca
New guidelines for early detection
2. THE PSA DISCUSSION
In an effort to clarify mixed messaging surrounding the early detection of prostate cancer, Prostate Cancer Canada, in
association with the Canadian Urologist Association Patient Information Committee, has created a document that outlines
the importance of diagnostic tools, when and how they should be used and the general importance of early detection.
Like most cancer diagnostic tools, the PSA blood test comes with its pros and cons; however, men deserve the right
to make their own informed decisions regarding the state of their health – even if that decision is to forego or delay
treatment. Informed decisions are impossible, however, without regular PSA blood tests and digital rectal examinations
(DRE) to assess the likelihood of cancer.
1. EARLY DETECTION OF PROSTATE CANCER
The PSA blood test is neither a test for prostate cancer nor an indicator of the type of prostate cancer. PSA levels in
the blood increase when the size of the prostate or the number of prostate cells increases.
Prostate Cancer Canada advises men and their doctors take the time to discuss the merits of prostate specific
antigen (PSA) blood testing followed by a digital rectal examination (DRE) for early detection of prostate cancer.
We also strongly recommend that men consider the following schedule for prostate cancer monitoring using PSA
blood testing:
The usefulness of the test has been debated in medical and political circles for some time. Therefore, when deciding
whether to take the test, men should consider the pros and cons and take into account age, risk factors and general
health.
AGE 40: Establish a baseline PSA value. While the threat of prostate cancer is minimal at this age, it also precedes the
onset of benign prostatic hyperplasia (BPH), the natural enlargement of the prostate that commonly occurs with age.
The onset of BPH often results in rising PSA over time, and can be confused with the onset of prostate cancer.
Your doctor can observe whether your PSA levels have risen, and if so, how quickly.
08
Unless your resulting baseline PSA score is of concern to your doctor, the PSA need only be repeated every 5 years until
age 50. Men at higher risk of prostate cancer (eg. men whose father and/or brother developed prostate cancer and/or
those of African or Caribbean descent) should begin annual PSA and DRE monitoring at age 40.
AGE 50: All men should begin annual or semiannual PSA monitoring if they have not yet done so. A minimal
increase in PSA levels against your baseline score often (in consultation with your physician) requires no further action
until your next annual test. A significant increase should prompt a discussion with your doctor or urologist about follow up
PSA blood tests.
The PSA blood test not only helps to diagnose prostate cancer, but helps monitor for recurrence of prostate cancer after
treatment. It allows a patient and his doctor to monitor if cancer is suspected, if lifestyle changes have had an impact or if
cancer has regressed or spread.
Combining the results of PSA blood testing with DRE increases both the diagnostic power and the accuracy of these early
detection methods.
Pros
• Research has shown that a rapid rise in PSA levels over months or years is a very strong sign of aggressive prostate
cancer.
• By the time a man develops advanced prostate cancer, his PSA is almost always very high.
• Widespread testing results in early diagnosis – at the stage when the chances of a cure are good, and there are
more options for treatment (e.g. surgery, external radiation, brachytherapy).
• The test may not be foolproof but it is the best early detection tool we currently have.
09
Cons
• Sometimes increased PSA blood levels are present when clinically insignificant prostate cancers exist – tumors that
are smaller than 0.5cc in volume. These tumors may never become life threatening. A high PSA level can also signify
non-cancerous conditions. Biopsying these men and treating their cancers may in some cases cause more harm
than good.
• Normal PSA levels are arbitrary. Sometimes PSA levels may be below normal levels even when cancer is present.
3. WHAT DO THE NUMBERS MEAN?
The PSA blood test checks the blood for minute quantities of an enzyme called prostate specific antigen or PSA.
A higher than normal amount of PSA in the blood is a possible indicator of prostate cancer, although other conditions
of the prostate, such as benign prostatic hyperplasia and prostatitis, also elevate PSA levels.
Early Detection Guidelines, were approved by the PCC SMAC and the Canadian Urologist Association Patient
Information Committee.
prostatecancer.ca
3. Here are the general guidelines for PSA values:
4. RELIABILITY OF THE PSA BLOOD TEST
PSA level in nanograms per millilitreUsual description for average man
0 to 4 ng/ml 4 to 10 ng/ml 10 to 20 ng/ml Greater than 20 ng/ml Within the normal range
Slightly Elevated
Moderately elevated
Highly elevated
Remember, high PSA readings do not mean that you have prostate cancer. Many factors can contribute to an
abnormally high level of PSA in the blood, and the general guidelines presented above are usually adjusted for
some of these factors.
AGE
Aging increases the amount of PSA in the blood, so normal PSA levels are adjusted for age. Any PSA level of
under 4 nanograms per millilitre (ng/ml) used to be considered insignificant. With more knowledge about the
effects of aging on PSA levels, however, doctors would probably consider a reading of above 2.5 significant for a
45-year-old man and call for further testing.
The normal range of PSA levels for men in each age group:
10
Age Range in Years
40 to 49 years
50 to 59 years
60 to 69 years
70 to 79 years
PSA normal range in nanograms
per milliliter (ng/ml)
0 to 2.5 PSA
2.6 to 3.5 PSA
3.6 to 4.5 PSA
4.6 to 6.5 PSA
Age-and race-adjusted cut-off values for PSA (nglml)
40-49
50-59
60-69
70-80
2.0
3.0
4.0
5.0
Still, there is considerable controversy over the value of the PSA blood test. Some studies report that no prostate
cancer was found in 70 to 80 per cent of the men who had a biopsy because of an elevated PSA level. The medical
community calls a higher than normal PSA level with no evidence of prostate cancer a “false positive”. Also, some
researchers estimate that 20 per cent of prostate cancers would be missed if doctors relied only on PSA blood
test results. In other words, one out of every five men tested would have prostate cancer and a normal PSA level.
A PSA level in the normal range with the presence of prostate cancer is called a “false negative”.
There is also a misconception that the PSA blood test is not accurate. When the PSA blood test is conducted in
accordance with the instructions provided, accurate assay results should be obtained.
The PSA value is not diagnostic for prostate cancer. It should be used in conjunction with clinical evaluation, digital
rectal examination, and other laboratory tests or imaging techniques. If the PSA value is inconsistent with clinical
evidence, additional testing is suggested to confirm the result. Confirmation of prostate cancer can only be
determined by prostatic biopsy.
11
5. REFINEMENTS
RACE
A man’s race affects his risk of developing prostate cancer and the amount of prostate specific antigen that is within
the normal range. Today, doctors may consider both a man’s age and his race when determining whether his PSA
blood test result is unusual. The following table shows age-and race-adjusted cut-off values for PSA – or in other
words, the PSA levels at the top end of the normal range for men of particular ages and races.
AgeAsian men
So many factors can affect the level of prostate-specific antigen in the blood that one might ask whether the PSA
blood test is useful in the diagnosis of prostate cancer. The answer is a resounding yes. The PSA blood test, especially
when combined with a digital rectal examination (DRE), is a good indicator of the possibility of prostate cancer. The
PSA blood test does not predict either the presence or absence of prostate cancer, but it does alert men and their
physicians to the possibility of the presence of an early-stage cancer in the prostate.
Caucasian men
Men of African descent
2.5
3.5
4.5
6.5
2.0
4.0
4.5
5.5
Physicians have made refinements to the PSA blood test and to the analysis of PSA blood test results to improve its
reliability as an indicator of prostate cancer. Doctors now consider the speed at which PSA levels rise, how quickly
PSA levels double in amount (PSA doubling time), the sort of prostate-specific antigen in the blood (free versus total
PSA), and the amount of PSA in relation to the size of a man’s prostate (PSA density).
PSA doubling time: PSA doubling time relates PSA levels to time. It measures the time it takes for your PSA value
to double. Sometimes, PSA doubling time is helpful in pre-biopsy guesses about whether a man has cancer and
whether this cancer is likely to be aggressive or to have spread.
Percentage of Free to Total PSA (%fPSA): This measurement is a ratio comparing the amount of free PSA to
the total amount of PSA in the blood. Free PSA travels alone in the blood; it is not bound to any other blood proteins.
This unbound or free PSA comes from BPH, not prostate cancer. So the higher a man’s percentage of free PSA, the
less likely it is that prostate cancer is to blame. Testing for free PSA (called %fPSA in some medical reports) is useful
for men whose PSA level falls between 4 and 10, the grey area in which BPH could be the culprit. Readings of
prostatecancer.ca
greater than 25 per cent free PSA (25 %fPSA) indicate that much of the elevated PSA is caused by BPH. A reading
of under 10% suggests that prostate cancer is causing this elevation and, furthermore, that this cancer is probably
large and in need of immediate treatment.
PSA density (PSAD): This measurement compares the size of a man’s prostate, which is determined by a
transrectal ultrasound (TRUS), with his PSA level. In simple terms, the doctor divides the PSA value by the size
(or mass) of the prostate. If, for example, your PSA level is 4 and the size of your prostate in grams is 32, you
would divide 4 by 32 to get a PSA density of 0.125. Usually, a PSA density under 0.07 is considered fairly safe, one
between 0.07 and 0.15 could be attributable to either BPH or prostate cancer, and one above 0.15 indicates an
increased likelihood that cancer is present. Prostate volume measurements, and thus PSA densities, are subject to
TRUS operator/interpreter variability.
6. OTHER CONDITIONS OF THE PROSTATE
12
Benign prostatic hyperplasia (BPH) and prostatitis can also increase the amount of PSA found in a man’s blood. BPH,
a non-cancerous enlargement of the prostate, can elevate PSA levels because a larger prostate manufactures more
prostate-specific antigen. Also, any prostate condition can weaken the tissues in the prostate gland, allowing more
PSA to leak into the blood. Usually, PSA levels caused by BPH do not go as high as those caused by prostate cancer,
nor do the levels tend to rise as quickly. However, most likely, if you have a higher than normal PSA level or one
that is steadily rising, your doctor will discuss the value of having a prostate biopsy to determine whether cancer or
some other condition is to blame.
The nomograms behind the 12 PCATs have an average accuracy rate of 80 per cent, and are of significant benefit
to patients in that they eliminate bias and subjectivity that is inherent in the perspective of individual clinicians and
caregivers.
To create this program for Canadian men, Prostate Cancer Canada partnered with a team of highly recognized
researchers led by Dr. Pierre Karakiewicz, MD, urologist and director of the Cancer Prognostics and Health Outcomes
Unit at the University of Montreal Health Centre.
Information published on the Prostate Cancer Canada website is provided for informational and educational purposes
only. Information provided on this website, including information derived from the Prostate Cancer Assessment Tools
(PCATs) and the prostate cancer nomograms, is not designed or intended to constitute medical advice or to be used
for diagnosis. The PCATs are intended to provide information on your condition and to help inform your consultations
with medical professionals. The information obtained from this website should not be a substitute for medical advice
from a qualified medical professional.
Prostate Cancer Canada and the Centre Hospitalier de l’Université de Montréal assume no responsibility or liability for
any consequence resulting directly or indirectly for any action or inaction you take based on or made in reliance on
the information, services, or material on or linked to this site.
13
Prostatitis, an inflammation of the prostate, can also affect PSA levels. Because this inflammation can break down
tissues in the prostate gland, it can enable quite a bit of prostate-specific antigen to escape fairly quickly into the
blood. An acutely inflamed or infected prostate can increase a man’s PSA level to 100 nanograms per millilitre
(ng/ml) or higher. After treatment for prostatitis, it can take up to six months for PSA levels to return to normal.
7. ASSESSING PROSTATE CANCER RISK
Prostate Cancer Assessment Tools (PCATs) are based on nomograms published in the Journal of Urology to ensure
highly accurate assessments. Nomograms are paper-based decision-making statistical tools that are comprised of
information from thousands of real-life observations from documented prostate cancer cases.
The tools assist patients and physicians in decision-making by providing calculated predictions of the outcomes of
various stages of prostate cancer.
prostatecancer.ca
Thank you to our Donors
Donors (continued)
Prostate Cancer Canada would like to recognize all donors whose generosity helps support our cause. Through research,
public education, support and awareness, you are helping us become a global leader in the fight against prostate cancer.
Due to space limitations we do not have the opportunity to recognize all those who make our work possible. As a result,
this list includes donors who have made a financial contribution of $1,000 or more from April 1, 2009 to March 31, 2010.
Should you note any errors or omissions, please accept our most sincere apologies and contact us at 1-888-255-0333 ext 242.
Thank you.
$100,000 +
Canada Safeway Ltd.
Canadian Prostate Cancer
Network
Randy Remington Prostate Fund
$25,000 - $99,999
14
Bayer Inc.
CIBC
Estate of Austin Conway
Masonic Foundation of Ontario
Mr. Lube Foundation
RBC Foundation
Sanofi-Aventis Canada Inc.
Shorcan
The GlaxosmithKline
Foundation
The KPMG Foundation
The Richter Charitable
Foundation
$10,000 - $24,999
ACI Brands Inc.
Amgen Canada Inc.
Robert K. Barrett
British Columbia Foundation
for Prostate Disease
Cedarhurst Golf Club Inc.
Estate of Douglas Robert Wallis
Evald Torokvei Foundation
Fairmont Hotels & Resorts
Jack. J. Holtzman
Ontario Masons - Toronto
Humber Valley District
Penn West Energy
B. Myron Rusk
SCA North America/
Canada Inc
Schwartz & Co. Ltd.
Sportsgrants Inc.
The D. H. Gordon Foundation
The HYDRECS Fund
The Survivors Prostate Cancer
Golf Tournament
Whitlock Motorsports
$5,000 - $9,999
Abbott Laboratories
Canada Ltd.
Avison Young Commercial
Real Estate (Ontario) Inc.
Barrick Heart of Gold Fund
Lynn Bevan
BMO Capital Markets
BMO Employee Charitable
Foundation
Brookfield Partners Foundation
Canadian Western Bank
Daytona Capital Corp.
Deloitte & Touche LLP
Enbridge Gas Distribution Inc.
Endla & John Gilmour Foundation
Rochelle Feldberg
Jeffrey Feldberg
First National Financial LP
Grafton-Fraser Inc.
John R. Ing
ING Real Estate Canada LP
Leon’s Furniture Limited
Michael Lewicki
Gary MacDonald
Mercedes-Benz Canada Inc.
Philip P. Mostowich
Oakah and Dorothy Jones
Foundation
Ontario Masons - York District
Osler, Hoskin & Harcourt LLP
Neil Parkinson
Prostate Cancer Foundation BC
GeorgeRatner
Rio Can Real Estate
Investment Trust
RSM RUV Management
Zachary Samuels
Stikeman Elliot LLP
T. A. Tait
TD Bank Financial Group
The Bolt Supply House Ltd.
The Charles Norcliffe and
Thelma Scott Baker
Foundation
TSX Group
$2,500 - $4,999
ARC Energy Trust
Jim Armstrong
Avalon Prostate Cancer
Support Group
BalancePlus Sliders Inc.
C.H.A.T. Student Council
Audrey Cameron
Gregory Collings
Paul Collings
Kevin Dancy
Eclipse Medical Inc.
Encore Wire Corporation
Estate of Christopher E. J.
Humphreys
Yves Fradet
Nedo A. Gizzi
Godfrey Family Foundation
Goldcorp Inc.
Golf Town
Ruben Goulart
Stephen Graham
Deborah Harper
Haywood Securities Inc.
Eleanor Holt
Intuit Canada Limited
Donation Matching Program
Tom Kierans
Randy Magnussen
F. R. Matthews
Peter Myers
Ontario Masons - St. Thomas
District
Murray Pask
Patrick and Barbara Keenan
Foundation
Donald B. Peart
Henry Piworowicz
Prime Projects Ltd.
Curtis Prosko
Richard Rooney
Shipp Corporation Ltd.
George Smith
Robert Sutherland
The J.E. Panneton Family
Foundation
Tom’s Place
VS LLP
Daniel Walshe
Thomas C. Wright
$1,000 - $2,499
2102583 Ontario
A Night To End Prostate Cancer
A & A King Family Foundation
Bill Acton
AGF Management Limited
Allan Berj And Mombee
American Medical Systems
Canada Inc.
J. C. Anderson
Gord Angevine
AON Reed Stenhouse Inc.
Armco Capital
James Ayearst
Ted Bailey
Arthur & Elle Bargen
Marina Barnstijn
David Beamish
Paul Beeston
Norman B Bell
Douglas Bennett
Ben’s Pharmacy
Roland Bertin
John Bigham
BMO Bank of Montreal
Boston Pizza
Bowne of Canada Ltd.
George Brazier
Arvey Brenner
Wesley P. Brown
Sandee Butterley
Lowrey A. Cain
Robert Cain
John A Campbell
Canadian Cancer Society
Capital Packers Inc.
Brian Carr
Leslie Carter
Michael F Casey
Tim W Casgrain
Yves Chabot
Jack Chisvin
Church of Our Saviour
The Redeemer
Andrew D. Clarke
Richard Clarke
Edward G Cleather
J.B. Colburn
Allan Collings
William A Corbett
E H Crawford
Credit Union Atlantic
Crestview Chrysler Dodge Jeep
John & Mary Crocker
Bob Cronin
Warren Crosbie
Rob Daniel
Gord Davis
Dell Direct Giving Program
Stan Doel
John Dove
Dover Flour
Lorne Dubros
Brian Dunn
Eddie’s Men’s Wear Ltd.
Edmonton Exchanger &
Manufacturing Ltd.
EnCana Cares Foundation
Engineering Student Society “A”
Eric Van Viegen
Deborah Evans
Howard Evans
Eyelogic Systems Inc.
Ron Fath
Saul Feldberg
Bernie Ferbey
Mario Ferrara
George Fink
Michael Fiorino
Shawn Fitzpatrick
Fleming Foundation
Henry Fong
Franklin Templeton Investments
Front Street Capital 2004
George Gagnon
Duane Gee
GM Verge Investments
Goodmans LLP
George Gosbee
Michael J. Gough
Theresa Gouthro
Green Hunt Wedlake Inc.
Randy Gregory
Brenda Groves
Barry J Gunn
Norman R Hain
Harley Hotchkiss
Robert C. Howard
I.M.P. Group Ltd.
IBM Canada Ltd.
Catherine Inglis
Iona Resources Holdings Inc.
Kevin Irons
Kristian Isberg
Bengt Jansson
Jardine Lloyd Thompson
Canada Inc.
Bruce Jenkins
Jonel jim Construction
Wendy Jones
Michael Kearns
Hubert Keenleyside
Jim & RonaKehoe
Kevin Kimsa
Kiwanis Club of Calgary Chinook
Kevin Knight
Tom Knowlton
Saul Korman
Korry’s Clothiers to Gentlemen
KPMG
T. H. Laidlaw
Leddy Exploration Limited
Leipert Financial Group
David H Lewis
Londonderry Chrysler
James A Lore
Nancy Love
Allan Lundell
Manfred Lupke
Dan J MacDonald
Mackie Research Capital
Corporation
Andrew Maitland
John Mandrusiak
Paul Marchildon
Marco Maritimes Ltd.
Lori Martai
Fasken Martineau
Ronald & Marlene Masleck
Mastermind Toys
Gordon Mauchel
McCarthy Tetrault LLP
John & Deni McCrae
15
prostatecancer.ca
board of directors /
senior management
Donors (continued)
16
Isabell McDorman
Donald McGregor
Hugh McLean
Gary M & Beverley McLeod
Peter And Fern Mcmahon/
Holland
Douglas J Mervyn
Mark Mettrick
Thomas Miller
Morneau Sobeco
Scott Morrison
Nelson Lumber
Darrell Newton
Nexans Canada Inc.
NLS Welding and Contracting Inc.
Northern Cables Inc.
Sean Nother
Nova Scotia Power
Taryn O’Brien
Ontario Masons - Grey District
Ontario Power Generation Inc.
Order of the Eastern Star, Tweed
Chapter #148
Neil Parkinson
David Pauli
Malcolm Peake
Ed Pearce
Ian Pearce
Terry S. Peters
Jon Picken
Provincial Industrial Roofing
ProWerx Disposal Ltd.
Geroge Przybylowski
R. Magnussen Consulting Ltd.
RBC Dominion Securities Inc.
Rio Tinto Alcan Inc.
C E Ritchie
Rob Ritchie
Rogers Group of Companies
William Ross
Ryan ULC
Mark Sack
James S. Saloman
SAS
Saskatchewan Gaming
Corporation
SaskTel
Sayal Charitable Foundation
Shadowcorp Investments
Limited
Ken Shannon
Shawflex
Sherebrooke Investments
Limited
Robert Shiell
Signature Capital
James Sinneave
Rick Kenneth Skauge
Craig Kenneth Skauge
Tom A Skinner
Sleepy Hollow Country Club Ltd.
Howard Sokolowski
St. Andrew’s East Golf and
Country Club
A. Steele
Hellyer’s Food Market
Steve & Kathy Hellyer
Stikeman Elliott - Calgary
Stone & Co. Ltd.
Summit Vale and Controls Inc.
Super Cue Billiards & Golf
Judy Sutherland
Joey Tanenbaum
Stephan Tapp
TELUS
The Barnes Family Charitable
Foundation
The Charitable Gift Funds
Canada Foundation
The Data Group of Companies
The Duguid Family Fund
The Jewish Foundation of
Manitoba
The Leonard Albert Family
Foundation
The McGraw Hill Companies
Thomas, Large & Singer Inc
Tickets-Beer For a Cure
Toronto Hydro Corporation
Toronto Police Amateur Athletic
Association
Ken Travis
Edward D Trewin
Truwan Management Limited
Ultimate Fitness Inc.
Theo Van der Kwast
Veroli Cultural Society
Melvin Vogel
Rod P. Wacowich
Lee And Nancy Watchorn
James W. Watt
Wellington West Capital Markets
Michael Williams
Alfred Wirth
James Wolfe
World Trade Centre
Timothy A. Wright
April 1, 2009 - March 31, 2010
Lee Watchorn, Chair
Jack Brill
Andrew D. Clarke, Vice Chair
Dr. Robert Bristow, Chair
Mark Dailey, Director
Dr. Yves Fradet, Chair
Tom Godber, Director
Michael J.Gough, Director
Stephen Graham, Vice Chair
Eileen Greene
Gordon I. Kirke, Director
Dr. Laurence Klotz, Chair
Senior Management
Steve Jones
President & CEO
Prostate Cancer Canada
Rebecca von Goetz
Vice President,
Marketing & Communications
Prostate Cancer Canada
Rocco Fazzolari
Vice President,
Finance & Administration
Prostate Cancer Canada
Donald McInnes
Ian MacVicar, Treasurer & Secretary
Patrick Meneley, Chair
Peter Myers
Ted Nash
Neil Parkinson
George Przybylowski, Chair
Pradeep Sood, Director
Robert Watson
Robert Zed, Director
Steve Jones, President & CEO
Scientific & medical
advisory committee
Dr. Yves Fradet
Chair, Uro-oncologist
Dr. Colleen C. Nelson
Vice Chair, Basic Scientist
Dr. Robert Bristow
Radiation Oncologist
Dr. Kim N Chi
Medical Oncologist
Dr. Joseph Chin
Uro-oncologist
Dr. Laurence Klotz
Uro-oncologist
Clinician Scientist
Award Panel
Dr. Laurence Klotz, Chair
Dr. Armen G. Aprikian
Dr. Robert Bristow
Dr. Scott North
Dr. Tom Pickles
Dr. Jeremy Squire
Dr. Danny Vesprini
Science Officer
Dr. Eric Winquist
Networks & Partnerships
Committee
Pilot Grant Panel
Dr. Yves Fradet, Chair
Dr. Kim Chi
Vice Chair, Clinical
Dr. Colleen Nelson
Vice Chair, Basic
Dr. Tarek Bismar
John Blanchard
Dr. Mario Chevrette
Dr. James R. Davie
Dr. Gerardo Ferbeyre
Dr. Michael Fraser
Science Officer
Dr. Masoom A Haider
Dr. Jeffrey Medin
Dr. Matthew Bruce
Parliament
Dr. Tom Pickles
Dr. Michael Pollak
Dr. Alan So
Dr. Emma
Thomlinson Guns
Dr. Theodorus
H. Van Der Kwast
Dr. Vasundara
Dr. Venkateswaran
Dr. Robert Bristow, Chair
Dr. Armen Aprikian
Dr. Mario Chevrette
Dr. Stuart Edmonds
Dr. Larry Goldenberg
Emma Halls
Professor John Mills
Dr. Colleen Nelson
Dr. Fred Saad
Dr. Howard Soule
Dr. Christine Williams
17
Patient & Public
Education Committee
Dr. Joseph Chin, Chair
Dr. David G. Bell
Dr. Bryan Donnelly
Dr. Pierre Karakiewicz
Dr. Andrew Loblaw
Dr. Robert Siemens
Dr. Peter Venner
Peter Pommerville
Bob Shiell
Dr. Peter Venner
Rebecca von Goetz
For biographies of committee members, please visit prostatecancer.ca
prostatecancer.ca
PROSTATE CANCER CANADA
CONDENSED FINANCIAL STATEMENTS
CONDENSED BALANCE SHEET
For 12 months ending March 31, 2010
Current Assets
Capital Assets
2009/10
$’000s
2008/09
$’000s
11,708 127 6,073
173
Total Assets
11,835 6,246
Liabilities (note 2)
5,937 3,777
Net Assets (note 3)
5,898 2,469
18
Total Liabilities and Assets
11,835 6,246
CONDENSED STATEMENT OF OPERATIONS AND CHANGES TO NET ASSETS
For 12 months ending March 31, 2010
2009/10
2008/09
Gross Revenue
Charitable Programs (note 4)
14,768 6,884 8,389
3,077
Net Revenue Before Expenses
7,884 5,312
Expenses (Fundraising, management and general administration)
4,455 3,341
Net Surplus After Expenses
3,429 1,971
Net Assets Start of Year
2,469 498
Net Assets End of Year
5,898 2,469 NOTES TO CONDENSED FINANCIAL STATEMENTS
1. The condensed financial statements are derived from the financial statements audited by Deloitte & Touche.
Copies of the audited statements are available on request. Certain prior year’s figures have been reclassified to
conform with current year’s presentation.
2. The Foundation funds research grants and projects. Current liabilities include a provisional amount of $5,106,012 for
research.
3. Net Assets include a Research Reserve Fund of $4,680,000, established to fund new prostate cancer related projects.
4. Charitable Programs include mission investments in research, support groups and public education.